A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant

Trial Profile

A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir Fixed-Dose Combination + Ribavirin Administered in Subjects Infected With Chronic HCV Who Have Advanced Liver Disease or Are Post-Liver Transplant

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SOLAR-1
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 24 Oct 2017 Results of pooled analysis of SOLAR-1, SOLAR-2, ASTRAL-4 and GS-US-334-0125 trials assessing predictive features of clinical improvement or deterioration presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 24 May 2016 Results of a pooled analysis of SOLAR-1 and SOLAR-2 studies presented at the Digestive Disease Week 2016
    • 17 Apr 2016 Pooled efficacy analysis of SOLAR-1 and SOLAR-2 studies (n=17), assessing outcomes in patients who underwent liver transplant after initiating treatment, were presented at The International Liver Congress™ 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top